Both single and dual antiplatelet therapy (DAPT)—typically aspirin and P2Y12 inhibitor—have proven effective in reducing cardiovascular events for patients with CAD, peripheral artery disease (PAD) and cerebrovascular disease [121,122]. This evidence concerns the gene P2RY12 and peripheral arterial disease.